TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
TRIMPACT: A Prospective Real-World Study of Atezolizumab Monotherapy as First-Line (Stage IV) Treatment in Patients With Non-Small Cell Lung Cancer With PD-L1 Tumor Cell Expression ≥50% and No Targetable Mutations
1 other identifier
observational
150
1 country
25
Brief Summary
This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2025
Typical duration for all trials
25 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 15, 2025
CompletedFirst Submitted
Initial submission to the registry
December 1, 2025
CompletedFirst Posted
Study publicly available on registry
December 12, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2027
April 30, 2026
December 1, 2025
1.6 years
December 1, 2025
April 29, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall Survival (OS)
Overall survival (OS) is defined as the time from the initiation of atezolizumab treatment to the date of death from any cause.
Up to 24 months
Secondary Outcomes (7)
Progression-Free Survival (PFS)
Up to 24 months
Objective Response Rate (ORR)
Up to 24 months
Disease Control Rate (DCR)
Up to 24 months
Duration of Response (DoR)
Up to 24 months
One-year Overall Survival (1-year OS)
12 months
- +2 more secondary outcomes
Study Arms (1)
Atezolizumab Real-World Cohort
This observational cohort consists of patients with stage IV non-small cell lung cancer (NSCLC) who receive first-line atezolizumab in routine clinical practice. Participants are included based on real-world treatment decisions made by their physicians, and no study-mandated interventions or procedures are required. The cohort reflects patients treated according to local standards of care, allowing evaluation of real-life treatment patterns, clinical outcomes, and safety in this population.
Eligibility Criteria
Adult patients with stage IV non-small cell lung cancer receiving first-line atezolizumab as part of routine clinical practice at participating oncology centers in Türkiye. The study population reflects real-world patients treated according to local standards of care.
You may qualify if:
- Signed informed consent form.
- Diagnosis of stage IV non-small cell lung cancer.
- Male or female patients aged 18 years or older.
- Patients who have been prescribed atezolizumab in accordance with routine clinical practice and the locally approved indication in Türkiye.
- Patients who have received up to 3 cycles of atezolizumab at the screening visit.
You may not qualify if:
- Patients who are not receiving atezolizumab for the treatment of lung cancer according to standard of care and the approved indication.
- Known or suspected hypersensitivity to atezolizumab.
- Pregnant or breastfeeding women.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Antalya Training and Research Hospitallead
- Hoffmann-La Rochecollaborator
Study Sites (25)
Adana City Hospital
Adana, Turkey (Türkiye)
Afyonkarahisar Health Sciences University Hospital
Afyonkarahisar, 03100, Turkey (Türkiye)
Ankara Oncology Training and Research Hospital
Ankara, 06200, Turkey (Türkiye)
Memorial Ankara Hospital
Ankara, 06560, Turkey (Türkiye)
Ankara Bilkent City Hospital
Ankara, 06800, Turkey (Türkiye)
Ankara Atatürk Sanatoryum Training and Research Hospital
Ankara, Turkey (Türkiye)
Antalya Training and Research Hospital
Antalya, 07100, Turkey (Türkiye)
Antalya City Hospital
Antalya, Turkey (Türkiye)
Adnan Menderes University Faculty of Medicine Hospital
Aydin, 09100, Turkey (Türkiye)
Dicle University Hospital
Diyarbakır, 21280, Turkey (Türkiye)
Trakya University Faculty of Medicine Hospital
Edirne, 22030, Turkey (Türkiye)
Gaziantep City Hospital
Gaziantep, Turkey (Türkiye)
Bahçelievler Memorial Hospital
Istanbul, 34180, Turkey (Türkiye)
İstanbul Medipol Mega Hospital
Istanbul, 34214, Turkey (Türkiye)
Ümraniye Training and Research Hospital
Istanbul, 34766, Turkey (Türkiye)
Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi
Istanbul, 34899, Turkey (Türkiye)
Başakşehir Çam and Sakura City Hospital
Istanbul, Turkey (Türkiye)
Dokuz Eylul University Faculty of Medicine Hospital
Izmir, 35340, Turkey (Türkiye)
Ege University Hospital
Izmir, Turkey (Türkiye)
Necmettin Erbakan University Meram Faculty of Medicine Hospital
Konya, 42080, Turkey (Türkiye)
Mersin University Faculty of Medicine Hospital
Mersin, 33110, Turkey (Türkiye)
Ordu State Hospital
Ordu, 52200, Turkey (Türkiye)
Sakarya University Faculty of Medicine Hospital
Sakarya, 54050, Turkey (Türkiye)
Medical Park Samsun Hospital
Samsun, 55080, Turkey (Türkiye)
Karadeniz Technical University Farabi Hospital
Trabzon, 61080, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
December 1, 2025
First Posted
December 12, 2025
Study Start
September 15, 2025
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
October 1, 2027
Last Updated
April 30, 2026
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share